If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
=== CDK independent functions === Independent of CDK, cyclin D1 binds to nuclear receptors (including estrogen receptor α, thyroid hormone receptor, PPARγ and AR) to regulate cell proliferation, growth, and differentiation. Cyclin D1 also binds to histone acetylases and histone deacetylases to regulate cell proliferation and cell differentiation genes in the early to mid-G1 phase.
The gabapentinoids are 3-substituted derivatives of GABA; hence, they are GABA analogues, as well as γ-amino acids. Specifically, pregabalin is (S)-(+)-3-isobutyl-GABA, phenibut is 3-phenyl-GABA, and gabapentin is a derivative of GABA with a cyclohexane ring at the 3 position (or, somewhat inappropriately named, 3-cyclohexyl-GABA). Recently, a detailed three dimensional molecular structure of the α2δ-1 protein with gabapentin and alternatively with L-leucine bound at the gabapentinoid binding site has been published PDB: 8FD7. These show that drugs bind to the first calcium channel and chemotaxis (Cache) domain in the α2 part of the α2δ-1. A very similar study shows the structure of α2δ-1 structure with mirogabalin bound. These studies also suggests that the L-leucine bound structure is slightly different than the drug bound structure, consistent with L-leucine acting as an antagonist to gabapentinoid drugs. The gabapentinoids also closely resemble the α-amino acids L-leucine and L-isoleucine, and this may be of greater relevance in relation to their pharmacodynamics than their structural similarity to GABA.
N-Desethylfluornitrazene (DFNZ or D-FNZ) is an atypical opioid analgesic of the nitazene family related to etonitazene. It is the N-desethyl analogue of fluornitazene (FNZ). DFNZ is the major active metabolite of FNZ, which appears to act as a prodrug of DFNZ. The drug is a highly selective superagonist of the μ-opioid receptor (MOR), with an affinity (Ki) of 1.0 nM, an EC50Tooltip half-maximal effective concentration of 1.66 to 8.49 nM, and an EmaxTooltip maximal efficacy of 104 to 119%. It shows some biased agonism at the MOR, preferring G protein to β-arrestin signaling. DFNZ shows a unique spatiotemporal pattern of MOR activation in vivo. It exhibits central permeability, but has impaired brain penetrance and thus some peripheral selectivity. The drug is a substrate of both P-glycoprotein and breast cancer resistance protein (BCRP), in contrast to FNZ, and this is responsible for its reduced capacity to cross the blood–brain barrier. Due to its peripheral selectivity, it shows limited MOR occupancy in the brain in rodents. DFNZ produces strong analgesic effects in rodents. It also produces antiallodynic effects, induces hyperlocomotion, and substitutes for heroin, thereby reducing heroin self-administration. Conversely, the drug does not produce respiratory depression, does not cause brain hypoxia at analgesic doses, does not downregulate the MOR, produces little or no tolerance and withdrawal, and shows weak reinforcing effects in rodents.
Airways, including hilar adenopathy or enlargement Breast shadows Bones, e.g. rib fractures and lytic bone lesions Cardiac silhouette, detecting cardiac enlargement Costophrenic angles, including pleural effusions Diaphragm, e.g. evidence of free air, indicative of perforation of an abdominal viscus Edges, e.g. apices for fibrosis, pneumothorax, pleural thickening or plaques Extrathoracic tissues Fields (lung parenchyma), being evidence of alveolar flooding Failure, e.g. alveolar air space disease with prominent vascularity with or without pleural effusions
== History == The syndrome is named after Edward Treacher Collins (1862–1932), the English surgeon and ophthalmologist who described its essential traits in 1900. In 1949, Adolphe Franceschetti and David Klein described the same condition on their own observations as mandibulofacial dysostosis. The term mandibulofacial dysostosis is used to describe the clinical features.
Sources: en.wikipedia.org
This material comprises coordinatively saturated Zn4O nodes and fully complexed BDC struts (see above for abbreviation); yet it apparently catalyzes the Friedel–Crafts tert-butylation of both toluene and biphenyl. Furthermore, para alkylation is strongly favored over ortho alkylation, a behavior thought to reflect the encapsulation of reactants by the MOF.
Common aqueous acids include hydrochloric acid (a solution of hydrogen chloride that is found in gastric acid in the stomach and activates digestive enzymes), acetic acid (vinegar is a dilute aqueous solution of this liquid), sulfuric acid (used in car batteries), and citric acid (found in citrus fruits). As these examples show, acids (in the colloquial sense) can be solutions or pure substances, and can be derived from acids (in the strict sense) that are solids, liquids, or gases. Strong acids and some concentrated weak acids are corrosive, but there are exceptions such as carboranes and boric acid. The second category of acids are Lewis acids, which form a covalent bond with an electron pair. An example is boron trifluoride (BF3), whose boron atom has a vacant orbital that can form a covalent bond by sharing a lone pair of electrons on an atom in a base, for example the nitrogen atom in ammonia (NH3). Lewis considered this as a generalization of the Brønsted definition, so that an acid is a chemical species that accepts electron pairs either directly or by releasing protons (H+) into the solution, which then accept electron pairs. Hydrogen chloride, acetic acid, and most other Brønsted–Lowry acids cannot form a covalent bond with an electron pair, however, and are therefore not Lewis acids. Conversely, many Lewis acids are not Arrhenius or Brønsted–Lowry acids. In modern terminology, an acid is implicitly a Brønsted acid and not a Lewis acid, since chemists almost always refer to a Lewis acid explicitly as such.
A coalition of forces opposing Iraq's aggression was formed, consisting of forces from 42 countries: Argentina, Australia, Bahrain, Bangladesh, Belgium, Canada, Czechoslovakia, Denmark, Egypt, France, Germany, Greece, Honduras, Hungary, Italy, Japan, Kuwait, Luxembourg, Morocco, the Netherlands, New Zealand, Niger, Norway, Oman, Pakistan, the Philippines, Poland, Portugal, Qatar, Romania, Saudi Arabia, Senegal, Sierra Leone, Singapore, South Korea, Spain, Sweden, Syria, Turkey, the United Arab Emirates, the UK and US. It was the largest coalition since World War II. A group of Afghan mujahideen soldiers also reportedly joined towards the end of the war. Although they did not contribute forces, Japan and Germany made financial contributions totaling $10 billion and $6.6 billion respectively. Luxembourg provided financial support. US troops represented 73% of the coalition's 956,600 troops in Iraq. A pact between the Indian government and the US also allowed US C-141 aircraft flying in materials from the Philippines to stop in Mumbai to refuel, which led to disquiet within most of the nation's formerly pro-Iraqi stance. US Army General Norman Schwarzkopf, Jr. was designated to be the commander of the coalition forces. The Soviet Union condemned Baghdad's aggression against Kuwait, but did not support the US and allied intervention in Iraq and tried to avert it. Many of the coalition countries were reluctant to commit military forces. Some felt that the war was an internal Arab affair or did not want to increase US influence in the Middle East.
When they pupate, they attach to the undersides of leaves and form a silky cocoon. This stage can last 4–13 days, depending on the temperature of the environment. Male pupae are slightly larger than female.
The Economic Times cited surveys showing "broad negative sentiment" about the economy, and Harris being "relentlessly hammered" by Trump during campaigns about this. The Economic Times cited University of Richmond School of Law professor Carl Tobias' appraisal of Trump's stance on immigration winning over Harris', and mentioned how Trump had increased his support from Hispanics, especially near the Mexican–American border and in areas impacted by recent immigration. Harris campaigning at multiple events with former Republican representative Liz Cheney has been suggested as a contributing factor as to why she lost. Los Angeles Times's Noah Bierman felt Harris could not overcome being the "turn the page" candidate, and cited former president Barack Obama's lead strategist David Axelrod, who said: "If you're the vice president of an administration people want to fire, you're way behind the eight-ball to start." Bierman wrote that besides criminal context, Trump "never followed a script, scoffed at the rules and spoke directly to the economic and cultural anxieties of the country". In The New York Times, Timothy Shenk argued that Democrats failed to articulate a vision for the future other than being against Trump and did not lean into a message of economic populism that polled best with swing voters, but also that the election looked more like a rejection of Biden than the embrace of Trump.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.